V.O. BITSADZE, S.V. AKINSHINA, M.D. ANDREEVA, A.D. MAKATSARIYA

I.M. Sechenov First Moscow State Medical University, 8 Trubetskaya St., bld.2, Moscow, Russian Federation 119991

Akinshina S.V. — Candidate of Medical Science, research associate of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-903-238-80-48, e-mail: gemostasis@mail.ru

Bitsadze V.O. — D.Med.Sc., Professor of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-926-231-38-29, e-mail: gemostasis@mail.ru

Andreeva M. D. — Candidate of Medical Science, doctoral candidate of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel. +7-918-388-61-11, e-mail: gemostasis@mail.ru

Makatsariya A.D. — D.Med.Sc., Professor, corresponding member of RAMS, Head of the Department of Obstetrics and Gynaecology of Public Health faculty, 62 Zemlyanoy Val St., bld.1., Moscow, Russian Federation 109004, tel.+7-903-728-08-97, e-mail: gemostasis@mail.ru

The article discusses the risk factors for thromboembolic complications before using assisted reproductive treatment. Herewith is evaluated the role of acquired and genetic defects of blood coagulation, as well as systemic inflammation response syndrome. Special focus is on the pathogenesis and clinical ovarian hyperstimulation syndrome. Personal and international experience in the prevention of thrombosis in patients enrolled in the IVF program is described.

Key words: thrombosis, reproductive technologies, acquired and genetic thrombophilia, ovarian hyperstimulation syndrome.

 

REFERENCES

1. Nelson S.M., Greer I.A. The potential role of heparin in assisted conception. Human Reproduction Update, 2008, vol. 14, no. 6, pp. 623-645. DOI:10.1093/humupd/dmn031.

2. Chan W.S., Ginsberg J.S. A review of upper extremity deep vein thrombosis in pregnancy: Unmasking the ‘ART’ behind the clot. Journal of Thrombosis and Haemostasis, 2006, vol. 4, no. 8, pp. 1673-1677. DOI: 10.1111/j.1538-7836.2006.02026.x.

3. Rogolino A., Coccia M.E., Fedi S., Gori A.M., et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: Possible association with clinical outcome. Blood Coagulation and Fibrinolysis, 2003, vol. 14, no. 3, pp. 277-282. DOI: 10.1097/00001721-200304000-00009.

4. Kodama H., Fukuda J., Karube H., et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertility and Sterility, 1996, vol. 66, no. 3, pp. 417-424.

5. Ricci G., Cerneca F., Simeone R., et al. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: An open-label, randomized, controlled trial. Human Reproduction, 2004, vol. 19, no. 4, pp. 838-848. DOI: 10.1093/humrep/deh185.

6. Rao A.K., Chitkara U., Milki A.A. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: A case report. Human Reproduction, 2005, vol. 20, no. 12, pp. 3307-3312. DOI: 10.1093/humrep/dei235.

7. Delvigne A., Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. International Journal of Fertility and Women’s Medicine, 2002, vol. 47, no. 5, pp. 211-226.

8. Avecillas J.F., Falcone T., Arroliga A.C. Ovarian hyperstimulation syndrome. Critical Care Clinics, 2004, vol. 20, no. 4, pp. 679-695. DOI: 10.1016/j.ccc.2004.05.003.

9. Dulitzky M., Cohen S.B., Inbal A., et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertility and Sterility, 2002, vol. 77, no. 3, pp. 463-467. DOI: 10.1016/S0015-0282(01)03218-6.

10. Qublan H.S., Eid S.S., Ababneh H.A. et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Human Reproduction, 2006, vol. 21, no. 10, pp. 2694-2698. DOI: 10.1093/humrep/del203.

11. Bitsadze V.O. Patogenez, printsipy diagnostiki i profilaktiki oslozhneniy beremennosti, obuslovlennykh trombofiliey. Dokt. med. nauk diss. Avtoref. [Pathogenesis, principles of diagnosis and prevention of pregnancy complications due to thrombophilia. Dr. med. sci. diss. Synopsis]. Moscow, 2004. 251 p.

12. Ou Y.C., Kao Y.L., Lai S.L., et al. Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: Case report. Human Reproduction, 2003, vol. 18, no. 11, pp. 2375-2381. DOI: 10.1093/humrep/deg470.

13. Enskog A., Henriksson M., Unander M., et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility, 1999, vol. 71, no. 5, pp. 808-814. DOI:10.1016/S0015-0282(99)00090-4.

14. Felberbaum R.E., Diedrich K. Gonadotrophin-releasing hormone antagonists: Will they replace the agonists? Reproductive BioMedicine Online, 2003, vol. 6, no. 1, pp. 43-53.

15. Polishuk W.Z., Schenker J.G. Ovarian overstimulation syndrome. Fertility and Sterility, 1969, vol. 20, no. 3, pp. 443-450.

16. Daniel Y., Geva E., Amit A., et al. Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. American Journal of Reproductive Immunology, 2001, vol. 45, no. 3, pp. 154-160.

17. Yan Z., Weich H.A., Bernart W., et al. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. Journal of Clinical Endocrinology and Metabolism, 1993, vol. 77, no. 6, pp. 1723-1725.

Journal of Clinical Endocrinology and Metabolism

18. Albert C., Garrido N., Mercader A., et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Molecular Human Reproduction, 2002, vol. 8, no. 5, pp. 409-418.

19. Rizk B., Aboulghar M., Smitz J., Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update, 1997, vol. 3, no. 3, pp. 255-266. DOI:10.1093/humupd/3.3.255.

20. Gordon J.D., Mesiano S., Zaloudek C.J., Jaffe RB. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. Journal of Clinical Endocrinology and Metabolism, 1996, vol. 81, no. 1, pp. 353-359.

21. Kamat B.R., Brown L.F., Manseau E.J., et al. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. American Journal of Pathology, 1995, vol. 146, no. 1, pp. 157-165.

22. Wang T.H., Horng S.G., Chang C.L., et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor Journal of Clinical Endocrinology and Metabolism, 2002, vol. 87, no. 7, pp. 3300-3308. DOI: 10.1210/jc.87.7.3300.

23. Todorow S., Schricker S.T., Siebzehnruebl E.R., Neidhardt B., Wildt L., Lang N. Von Willebrand factor: An endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome. Human Reproduction, 1993, vol. 8, no. 12, pp. 2039-2046.

24. Ogawa S., Minakami H., Araki S., Ohno T., et al. A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics, 2001, vol. 18, no. 2, pp. 114-119. DOI: 10.1023/A:1026590910462.

25. Balasch J., Arroyo V., Fábregues F. et al. Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Annals of Internal Medicine, 1994, vol. 121, no. 1, pp. 27-33.

26. Pellicer A., Albert C., Mercader A. et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertility and Sterility, 1999, vol. 71, no. 3, pp. 482-489.

27. Goldsman M.P., Pedram A., Dominguez C.E. et al. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertility and Sterility, 1995, vol. 63, no. 2, pp. 268-272.

28. Mathur R., Kailasam C., Jenkins J. Review of the evidence base strategies to prevent ovarian hyperstimulation syndrome. Human Fertility, 2007, vol. 10, no. 2, pp. 75-85. DOI: 10.1080/14647270601111239.

29. Yoshii F., Ooki N., Shinohara Y., et al. Multiple cerebral infarctions associated with ovarian hyperstimulation syndrome. Neurology, 1999, vol. 53, no. 1, pp. 225-227.

30. Cluroe A.D., Synek B.J.A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology, 1995, vol. 27, no. 4, pp. 344-346.

31. Abuzeid M.I., Nassar Z., Massaad Z., et al. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Human Reproduction, 2003, vol. 18, no. 2, pp. 370-373. DOI: 10.1093/humrep/deg074.

32. Abramov Y., Elchalal U., Schenker J.G. Febrile morbidity in severe and critical ovarian hyperstimulation syndrome: A multicentre study. Human Reproduction, 1998, vol. 13, no. 11, pp. 3128-3131.

33. Hitkari J.A., Rowe T.P., von Dadelszen P. Activated protein C and the ovarian hyperstimulation syndrome: Possible therapeutic implications. Medical Hypotheses, 2006, vol. 66, no. 5, pp. 929-933. DOI: 10.1016/j.mehy.2005.08.058.

34. Borenstein R., Elhalah U., Lunenfeld B., Schwartz Z.S. Severe ovarian hyperstimulation syndrome: A reevaluated therapeutic approach. Fertility and Sterility, 1989, vol. 51, no. 5, pp. 791-795.

35. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility, 1992, vol. 58, no. 2, pp. 249-261.

36. Gergely R.Z., Paldi E., Erlik Y., Makler A. Treatment of ovarian hyperstimulation syndrome by antihistamine. Obstetrics and Gynecology, 1976, vol. 47, no. 1, pp. 83-85.

37. Balasch J., Fabregues F., Arroyo V., Jimenez W., Creus M., Vanrell J.A. Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstetricia et Gynecologica Scandinavica, 1996, vol. 75, no. 7, pp. 662-667.

38. Chan W.S., Dixon M.E. The “ART” of thromboembolism: A review of assisted reproductive technology and thromboembolic complications. Thrombosis Research, 2008, vol.121, no. 6, pp. 713-726.DOI: 10.1016/j.thromres.2007.05.023.